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Abstract 
 
Cardiovascular disease (CVD) remains the leading cause of 
morbidity and mortality worldwide. Despite efforts to tackle 
CVD, its prevalence continues to escalate in almost every 
country. The problem requires an exploration of novel ways to 
uncover solutions. Health innovations that embrace new 
knowledge and technology possess the potential to 
revolutionize the management of CVD. Using findings from 
published studies on CVD, researchers generated innovations 
in the areas of global risk assessment, home and remote 
monitoring and bedside testing. The use of pharmacogenetics 
and methods to support lifestyle changes represent other 
potential topics for innovations. Gaps in existing knowledge 
and practice of CVD provide opportunities for the 
development of new ideas, practices and technology. 
However, healthcare professionals need to be cognisant of 
the limitations of health innovations and advocate for 
safeguarding patients’ wellbeing. 
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Introduction 
Cardiovascular disease (CVD) remains the leading cause of 
morbidity and mortality, not only in developed countries, but 
also in third world countries.
1
 CVD encompasses coronary 
artery disease, stroke and heart failure and results from a  
 
 
 
 
 
 
 
 
 
 
 
combination of risk factors -  some cannot be modified 
e.g. age, genetics and gender, whereas others are 
amenable to change e.g. diabetes mellitus, hypertension, 
obesity, dyslipidaemia and smoking. The lifetime risk of 
developing CVD considerably surpasses the lifetime risk of 
developing all cancers combined.
2,3
 CVD imposes an 
enormous burden on patients, their families and 
healthcare providers not only in terms of economic cost 
but also in terms of the social and psychological impact. 
   
Health innovation refers to the intentional introduction 
and application within a role, group, or organisation, of 
ideas, processes, products or procedures, new to the 
relevant unit of adoption, designed to significantly benefit 
the individual, group, or wider society.
4
 Innovation’s three 
salient characteristics encompass novelty, an application 
component and a projected benefit. Despite ongoing 
efforts to halt CVD, the prevalence continues to rise in 
almost every country.
5
 Innovative ways need to be 
explored to confront this problem. Health advancements 
that embrace new knowledge and technology can 
potentially modernize the management of CVD.  
 
In Malaysia, the prevalence of coronary heart disease 
increased three fold in the past 40 years.
 6 
Hypertension 
reached a staggering prevalence of 42.6% in 2006. and 
diabetes increased from a prevalence of 14.9% in 2006 to 
20.6% in 2011. This rising trend in CVD and the major risk 
factors creates concern and emphasises the need for 
novel interventions to counter the problem. 
 
Literature review  
Contemporary medicine initially focused on the treatment 
of symptoms of cardiovascular disease. After the 
identification of the multifaceted basis of the disease by 
the seminal Framingham study, the focus gradually 
shifted towards a prevention focus. Initially, efforts 
targeted single risk factors such as hypertension, 
hyperlipidemia and diabetes. Subsequently, medicine 
adopted the global risk factor approach. Research now 
advocates novel approaches such as combination pills and 
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the lifetime risk calculators. Technological advances in 
monitoring invaded the market place with home monitoring 
devices such as glucometers and blood pressure devices. Such 
devices immediately altered the way that doctors practice and 
manage patients. Innovations occurred in diagnostic testing 
and consisted of point of care tests such as the Troponin T/I 
test for the evaluation of acute chest pain. Many technological 
advances in medicine transpired in cardiology to improve 
mortality and morbidity from coronary artery disease.  
  
Potential areas for developing health innovation in CVD 
Several potential areas for health innovations development 
exists in CVD. The ensuing sections discuss projected spheres 
of advancement to transform healthcare in CVD.  
 
a) Pharmacogenetics 
A genetic family history of cardiovascular disease represents 
one of the major risk factors for developing the condition and 
illustrates the interaction between genes and the 
environment in the pathophysiology of the disease. In 
pharmacogenetics in oncology, doctors can already 
differentiate likely responders to a particular drug from non-
responders.The pharmacogenetics potential remains immense 
in terms of drug selection based on the genetic profile to 
control risk factors in patients with CVD. 
 
b) CVD Secondary Prevention (Screening and identification)  
Secondary prevention with accurate prediction of an 
individual’s risk of developing CVD remains the holy grail of 
cardiovascular risk assessment. Current technology only 
allows individual risk prediction to be extrapolated from 
population studies. Novel biomarkers and new diagnostic 
tools (cardiac scans) only minimally assist in risk prediction 
and early diagnosis. Present risk scoring translation means 
that in a 100 patients with a similar risk profile, 20 would 
develop a major cardiovascular event in ten years, 80 patients 
out of the 100 would not. Yet, all get targeted as high risk and 
receive management. Health innovations capable of 
identifying those at risk would allow targeting resources at the 
true high risk individuals and reduce overtreatment of false 
positives.   
 
c) Modification of risk factors in patients 
Changing patient behaviour continues to be a challenging and 
daunting task. One study found that 62% of smokers resumed 
smoking within a year after a myocardial infarction.
7
  
Individuals who continued smoking experience a threefold 
increased risk of dying compared with those who stop. 
Evidence supports the effectiveness of lifestyle interventions, 
but professionals need novel strategies and methods to 
intervene successfully in modifying dysfunctional lifestyle 
practices.
 8
 
d) Adherence to medication 
Greater than one in five patients discontinued use of 
aspirin, beta-blockers, or statins, and one in eight 
discontinued use of all three medications within one 
month after a myocardial infarction.
9
 Although health 
professionals attempted many different methods to 
improve adherence, a review showed that improvements 
failed to produce moderate increases even with the most 
effective methods.
10
 Healthcare providers need effective 
health innovations in this matter of critical patient self-
care.  
 
e) Paucity of information for developing countries 
Evidence and epidemiological data in the cardiovascular 
field comes mainly from research done in high income, 
developed countries. Yet, the low to middle income 
countries increasingly feel the overwhelming burden of 
CVD. The disease occurs more commonly in the poor and 
also contributes to poverty, creating a vicious cycle that 
impedes development.
5
 The developing countries 
urgently need cost-effective health innovations. When 
translating evidence-based low cost interventions to 
resource poor countries, research needs to show the 
ability to successfully implement the cost-effective 
innovation in the resource poor country.  
 
f) CVD management for specific populations  
Gaps exist in the knowledge and approach towards CVD 
management of specific populations such as women, 
indigenous people and the young. A perception about 
CVD being a disease of older white men persists despite 
evidence of increased prevalence in women and certain 
ethnic groups. Health innovations need to build in a plan 
for inclusion of these vulnerable populations to ensure 
the non-marginalization of those at risk.  
 
Barriers, challenges and facilitators in the health 
innovation  
Inertia to change remains a pervasive barrier to health 
innovation especially regarding the existing healthcare 
system and policy. These factors along with financial 
issues hinder the adoption of health innovations. For 
example, unhealthy lifestyle behaviour continues to be a 
major risk factor for CVD yet doctors and patients possess 
the awareness for the need to modify unhealthy 
behaviours. Despite comprehending these facts, doctors 
frequently cite health system barriers such as the lack of 
time or resources as the main reason for not promoting 
lifestyle interventions. Health innovations in the future 
will require the employment of complex intervention 
strategies to overcome multiple barriers in order to be 
successful. 
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Limitations of health innovation 
By virtue of their nature, health innovations require 
evaluation in practice prior to implementation. Cost-
effectiveness, acceptability and accessibility remain unknown 
until tested. Similarly, negative aspects or adverse events 
from health innovations may fail to be apparent in the initial 
stages until months or years after implementation as 
evidenced by drugs like thalidomide used in pregnancy for 
morning sickness that caused children to be born without 
limbs in the 1960s.
 11
 New modalities require on-going post-
marketing surveillance to detect any rise in morbidity and 
mortality. Technological health innovation potentially can also 
depersonalize patient care. Unforeseen consequences can 
arise such as a patient adopts incorrect self-care practices by 
finding inaccurate information online via search engines. 
Clinical practice may come to over rely on technology 
resulting in the loss of essential skills e.g. surgical expertise. 
Healthcare providers need to ensure adherence to the 
principles of ethics such as patient confidentiality, autonomy, 
beneficences and non-maleficence at all times in the 
implementation of health technological inventions. At all 
costs, the professional needs to preserve patient-centered 
care and decision making. 
 
Conclusions 
The 21
st
 century represents an exciting era for development of 
health innovations. Health innovators stay poised to confront 
the CVD epidemic. Gaps in existing knowledge and practice of 
CVD need to be viewed as opportunities for improving ideas, 
practices and technology. However, medical professionals 
must be cognisant of the limitations of new age inventions 
and safeguard patients’ well-being.   
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